CD44 and head and neck squamous cell carcinoma: Initially identified as a solid malignancy CSC marker in breast cancer [18], Prince et al. demonstrated that CD44 expression could also be used to isolate a tumor subpopulation with increased tumorigenicity in HNSCC [23].